Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)
Latest Information Update: 26 Sep 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURMOUNT-ADOLESCENTS
- Sponsors Eli Lilly and Company
Most Recent Events
- 25 Jun 2025 Planned End Date changed from 1 Oct 2026 to 1 Jul 2029.
- 25 Jun 2025 Planned primary completion date changed from 1 Oct 2026 to 1 May 2026.
- 25 Jun 2025 Status changed from recruiting to active, no longer recruiting.